

Cell Line Data Sheet for Rh18

Disease:	Rhabdomyosarcoma			
Histology Subtype:	Predominately Embryonal (Mixed Aveolar and Embryonal subtype)			
Phase of Therapy:	Diagnosis			
Treatment:	None			
Disease Stage:	4			
Gender:	N/A			
Age at diagnosis:	24 months			
Race:	N/A			
Age at sample collection:	N/A			
Source of Culture:	Solid tumor from mouse xenograft			
Primary Tumor Site:	Perineum			
Date Established:				
PAX-FKHR Status:	Positive for translocation			
p53 functionality:	Non-Functional			
Karyotype:				
Modal No:				
R-IC50 (DIMSCAN*):	<u>Vincristine (ng/ml)</u>	<u>Melphalan (µg/ml)</u>	<u>Etoposide (ng/ml)</u>	<u>Rapamycin (ng/ml)</u>
*see reference 1	0.19 ± 0.28	17.74 ± 1.38	18.80 ± 2.27	N/A
Growth Conditions:	Please see Protocols section at https://www.cccells.org/protocols.php 5% CO ₂ , 20% O ₂ , 37.0°C			
Media Formulation:	Please see Protocols section at https://www.cccells.org/protocols.php Cells are grown in a base medium of Iscove's Modified Dulbecco's Medium plus the following supplements (to a final concentration): 20% Fetal Bovine Serum, 4mM L-Glutamine, 1X ITS (5 µg/mL insulin, 5 µg/mL transferrin, 5 ng/mL selenous acid)			
Doubling Time:	65 hours			
Growth Properties:	Teardrop-shaped cells with processes, adherent			
STR Profile:	May be obtained at https://strdb.cccells.org/			
Notes:	Positive for MyoD1 and myogenin			

All COG Repository cell lines are antibiotic-free, mycoplasma-free, and cryopreserved in 50% FBS / 7.5% DMSO. Each vial label contains the cell line name, passage number, total viable cell count (usually 5-10e6), the overall cell viability, and date frozen. All cell lines are validated with original patient sample by STR analysis.



Cell Line Data Sheet for Rh18

References:

1. Kang MH, Smith MA, Morton CL, Keshelava N, Houghton PJ, Reynolds CP. National Cancer Institute Pediatric Preclinical Testing Program: Model Description for In Vitro Cytotoxicity Testing. *Pediatric Blood Cancer* 56: 239-249, 2011. PubMed ID: 20922763
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3005554/>

SEE NCI Pediatric Preclinical Testing Program references.

2. Petak, I., Douglas, L., Tillman, D.M., Vernes, R., Houghton, J.A. (2000). Pediatric rhabdomyosarcoma cell lines are resistant to Fas-induced apoptosis and highly sensitive to TRAIL-induced apoptosis. *Clin Cancer Res* 6, 4119-27. PMID:11051265
<https://clincancerres.aacrjournals.org/content/6/10/4119.long>
3. Hazelton, B.J., Houghton, J.A., Parham, D.M., Douglass, E.C., Torrance, P.M., Holt, H., Houghton, P.J. (1987). Characterization of Cell Lines Derived from Xenografts of Childhood Rhabdomyosarcoma. *Cancer Res* 47, 4501-7. PMID: 3607778
<https://cancerres.aacrjournals.org/content/47/16/4501.long>



Cell Line Data Sheet for Rh18

Cell Line Name: Rh18

Low confluency (10x magnification)

High confluency (10x magnification)

Low confluency (20x magnification)

High confluency (20x magnification)